查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1715307

良性前列腺增生藥物市場（按治療類型、產品類型和最終用戶分類）—2025 年至 2030 年全球預測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年良性前列腺增生治療市場價值將達到14.2億美元，到2025年將以5.91%的複合年成長率成長至15億美元，到2030年將達到20.1億美元。

主要市場統計數據
基準年2024年 14.2億美元
預計2025年 15億美元
預測年份 2030 20.1億美元
複合年成長率（%） 5.91%

良性前列腺增生 (BPH) 是影響很大一部分男性人口的重大健康挑戰，引發了廣泛的研究、創新的治療方法和不斷發展的臨床實踐。近年來，醫療技術的進步和患者意識的提高導致了 BPH 診斷和管理的模式轉移。隨著醫療保健相關人員努力尋求平衡有效性、患者舒適度和成本效益的解決方案，市場正在快速發展。過去，BPH 的治療是透過傳統的外科手術進行，而現在，BPH 的治療涵蓋了一系列治療方法，從藥物治療到尖端的微創手術。這項全面的分析探討了當前治療領域的多方面動態，並著重於臨床進展和市場趨勢。透過檢驗潛在的促進因素和阻礙因素，該報告旨在清楚了解治療創新和以患者為中心的方法如何再形成產業。以下部分深入探討變革性轉變、競爭考察、區域趨勢和競爭動態，並提出可行的建議，幫助產業領導者做出明智的策略決策。

重新定義治療方式與市場動態的轉型轉變

近年來，BPH 治療領域發生了變革性的變化，重新定義了臨床和市場動態。醫學正在迅速超越傳統方法，並採用優先考慮患者安全和改善治療結果的技術創新。依賴侵入性手術的傳統方法正逐漸被各種微創手術所取代，這些手術可以縮短恢復時間並最大限度地減少附帶組織損傷。研究人員和臨床醫生正在採用能夠提供精準和有針對性的療效的技術，創造以創新為關鍵的競爭性市場環境。

這種轉變受到多種因素的影響，包括醫學影像的進步、生物材料的改進以及手術過程中即時監控系統的整合。此外，患者人口結構的變化和對門診病人服務日益成長的需求正在推動支持更快康復和更短住院時間的技術的採用。隨著對基於價值的醫療的日益重視，市場正在積極致力於新治療方法的研發和監管支援。最終，這些趨勢正在突破治療效果的界限，同時最佳化整體患者照護，在複雜的技術創新和不斷發展的醫療規範中實現市場持續成長。

全面的細分洞察，推動市場滲透

BPH 治療的市場區隔在揭示清晰的市場趨勢和確定成熟的投資領域方面發揮關鍵作用。按治療類型分析市場時，可以看到藥物治療、微創治療和手術治療之間有明顯差異。藥物治療進一步分為5α-還原酶抑制劑和α-阻斷劑，它們繼續為手術提供非侵入性的替代方法。前列腺動脈栓塞和水蒸氣療法等微創療法已成為有希望的選擇，可在療效和快速恢復時間之間取得良好的平衡。相反，手術治療仍然至關重要，雷射手術、前列腺尿道抬高術、經尿道前列腺切開術和經尿道前列腺切除術等可為晚期病例提供明確的解決方案。

此外，基於產品類型的細分可以揭示推動該市場發展的眾多關鍵因素。導管、電極、植入、前列腺支架、電切鏡和泌尿系統雷射等醫療器材的技術創新顯著改善了手術結果和病人安全。基於最終用戶的細分進一步強調了應用程式根據設定的重要性，正如門診手術中心、診所和醫院的不同需求所見。全面了解這些細分市場可以為相關人員提供調整策略和利用動態 BPH 治療領域中新興機會所需的詳細見解。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 前列腺增生的發生率不斷上升，診斷水準不斷提高
      • 提高患者對有效非手術治療方案的認知與偏好
      • 擴大全球醫療保健基礎設施
    • 限制因素
      • 缺乏對良性攝護腺增生症狀的認知
    • 機會
      • 持續創新前列腺增生微創治療
      • 利用巨量資料分析增強前列腺增生的診斷和治療過程
    • 任務
      • 治療良性攝護腺增生的監管複雜性
  • 市場區隔分析
    • 治療類型：人們對結合藥物和外科手術治療來治療 BPH 的藥物的興趣日益濃厚。
    • 最終用戶：門診手術中心前列腺增大藥物的使用增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 良性攝護腺增生藥物市場（依治療類型）

  • 製藥
    • 5α-還原酶抑制劑
    • 阿爾法阻斷劑
  • 微創治療
    • 攝護腺動脈栓塞術
    • 水蒸氣療法
  • 手術治療
    • 雷射手術
    • 前列腺尿道提升術
    • 經尿道前列腺切開術
    • 經尿道前列腺切除術

第7章。良性攝護腺增生藥物市場（依產品類型）

  • 導管
  • 電極
  • 植入
  • 攝護腺支架
  • 電切鏡
  • 泌尿系統雷射

第8章 良性攝護腺增生藥物市場（依最終使用者）

  • 門診手術中心
  • 診所
  • 醫院

9.美洲良性前列腺增生症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10.亞太地區BPH藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

11.歐洲、中東和非洲BPH藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lumenis Ltd.
  • Lupin Pharmaceuticals
  • Medtronic PLC
  • Merck & Co., Inc.
  • Merit Medical Systems
  • Mylan NV
  • Olympus Corporation
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 1.42 billion in 2024 and is projected to grow to USD 1.50 billion in 2025, with a CAGR of 5.91%, reaching USD 2.01 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.42 billion
Estimated Year [2025] USD 1.50 billion
Forecast Year [2030] USD 2.01 billion
CAGR (%) 5.91%

Benign Prostatic Hyperplasia (BPH) represents a significant health challenge that affects a large segment of the male population, leading to extensive research, innovative therapies, and evolving clinical practices. In recent years, advances in medical technology and increased patient awareness have driven a paradigm shift in the diagnosis and management of BPH. The market is witnessing rapid evolution as healthcare stakeholders strive for solutions that balance efficacy, patient comfort, and cost-effectiveness. Historically managed through traditional surgical interventions, the treatment of BPH now embraces a spectrum of therapies ranging from pharmacological solutions to state-of-the-art minimally invasive procedures. This comprehensive analysis explores the multifaceted dynamics of the current treatment landscape, focusing on both clinical advancements and market trends. By examining the underlying drivers and impediments, this report aims to provide a clear understanding of how treatment innovations and patient-centric approaches are reshaping the industry. The following sections delve deeper into transformative shifts, segmentation insights, regional trends, and competitive dynamics, setting the stage for actionable recommendations to empower industry leaders in making informed strategic decisions.

Transformative Shifts Redefining Treatment Modalities and Market Dynamics

In recent years, the BPH treatment landscape has witnessed transformative shifts that are redefining both clinical practices and market dynamics. Medical science has rapidly progressed beyond conventional methods, embracing innovations that prioritize patient safety and enhanced therapeutic outcomes. The traditional reliance on invasive surgical procedures is gradually giving way to a myriad of minimally invasive treatments that reduce recovery time and minimize collateral tissue damage. Researchers and clinicians have embraced technologies that offer precision and targeted efficacy, thereby fostering a competitive market environment where innovation is key.

These shifts have been influenced by multiple factors including advancements in medical imaging, improved biomaterials, and the integration of real-time monitoring systems during procedures. Additionally, evolving patient demographics and increasing demand for outpatient services have driven the adoption of technologies that support quicker recovery and reduced hospital stays. As the emphasis on value-based care intensifies, the market is witnessing a strong commitment to research, development, and regulatory support for novel treatments. Ultimately, these trends are pushing boundaries in treatment efficacy while simultaneously optimizing overall patient care, positioning the market for sustained growth amidst a complex interplay of technological innovation and evolving healthcare norms.

Comprehensive Segmentation Insights Driving Market Penetration

The market segmentation of BPH treatments plays a critical role in illuminating distinct market trends and identifying areas ripe for investment. Analyzing the market based on treatment type, significant variation is observed across medications, minimally invasive therapies, and surgical treatments. Medications, which are further differentiated into 5-Alpha-Reductase Inhibitors and Alpha Blockers, continue to provide a non-invasive alternative to surgery. Minimally invasive therapies, including procedures such as Prostate Artery Embolization and Water Vapour Therapy, have emerged as promising options that strike a balance between efficacy and a reduced recovery period. In contrast, surgical treatments remain essential, with options like Laser Surgery, Prostatic Urethral Lift, Transurethral Incision Of The Prostate, and Transurethral Resection Of The Prostate offering definitive solutions in advanced cases.

Furthermore, segmentation based on product type has shed light on a wide range of critical components driving this market. Innovations in medical instruments such as Catheters, Electrodes, Implants, Prostatic Stents, Resectoscopes, and Urology Laser have significantly enhanced procedural outcomes and patient safety. Segmentation based on the end user further emphasizes the importance of setting-specific applications, with varying demands observed in Ambulatory Surgical Centers, Clinics, and Hospitals. An integrated understanding of these segmentations provides stakeholders with the granular insights needed to tailor strategies and capitalize on emerging opportunities within the dynamic BPH treatment arena.

Based on Treatment Type, market is studied across Medications, Minimally Invasive Therapies, and Surgical Treatments. The Medications is further studied across 5-Alpha-Reductase Inhibitors and Alpha Blockers. The Minimally Invasive Therapies is further studied across Prostate Artery Embolization and Water Vapour Therapy. The Surgical Treatments is further studied across Laser Surgery, Prostatic Urethral Lift, Transurethral Incision Of The Prostate, and Transurethral Resection Of The Prostate.

Based on Product Type, market is studied across Catheters, Electrodes, Implants, Prostatic Stents, Resectoscopes, and Urology Laser.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.

Regional Trends and Emerging Markets in a Dynamic Global Environment

The regional analysis of the BPH treatment market reveals a landscape where differing economic, demographic, and regulatory factors play pivotal roles in shaping growth trajectories. In the Americas, robust healthcare infrastructure and strong investments in medical technology foster a competitive environment marked by rapid adoption of innovative therapies. Market dynamics in this region reflect a high degree of clinical research, regulatory support, and a service-oriented approach to patient care.

Similarly, the Europe, Middle East & Africa region showcases a diverse spectrum of healthcare systems where policy reforms and investment in translational medicine are accelerating the implementation of both conventional and novel treatment modalities. Simultaneously, cultural nuances and varying degrees of access to advanced technology influence treatment choices and outcomes. The Asia-Pacific region offers a contrasting picture, characterized by burgeoning middle-class populations, rising incidence of BPH, and a significant push towards modernization of its healthcare delivery systems. Despite challenges related to infrastructure and regulatory harmonization, rapid urbanization and increased healthcare spending in this region are setting the stage for considerable market expansion. Together, these regional insights underscore the importance of tailored strategies that address local challenges while leveraging global innovation trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Strategic Insights from Leading Industry Innovators

A detailed review of the competitive environment in the BPH treatment market reveals a highly dynamic landscape where both multinational giants and specialized regional players are actively contributing to industry innovation. Leading companies such as Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, and Astellas Pharma Inc. are at the forefront of research and development, bringing forward new therapies and refining existing treatment protocols. Global players like Bayer AG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, and Cipla Ltd. have also significantly impacted market penetration through strategic collaborations and extensive clinical trials.

Other noteworthy companies include Dr. Reddy's Laboratories, Eli Lilly and Company, Endo International PLC, and GlaxoSmithKline plc, each of which has leveraged its expertise to enhance the overall treatment spectrum. This competitive set is further bolstered by innovators such as Hikma Pharmaceuticals PLC, Lumenis Ltd., Lupin Pharmaceuticals, Medtronic PLC, and Merck & Co., Inc., whose investments have led to improvements in both product design and procedural approaches. Additional industry leaders including Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd. contribute to a competitive landscape that is defined by relentless innovation, strategic market positioning, and an unwavering commitment to improving patient outcomes across the globe.

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Cipla Ltd., Dr. Reddy's Laboratories, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lumenis Ltd., Lupin Pharmaceuticals, Medtronic PLC, Merck & Co., Inc., Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Strategic Market Leadership

To navigate the complex dynamics of the BPH treatment market, industry leaders must adopt a forward-thinking strategy that capitalizes on current trends while anticipating future challenges. It is imperative to invest in research and development to continuously refine minimally invasive treatments and integrate state-of-the-art technologies that enhance procedural accuracy and patient safety. Fostering partnerships between clinical research entities, technology developers, and regulatory bodies can accelerate the translation of innovative therapies from the laboratory to the clinical setting.

Leaders should also consider a diversified portfolio approach that encompasses various treatment modalities and product types to mitigate risks and capture emerging opportunities. Emphasis on enhancing the patient journey through improved diagnostics, personalized treatment protocols, and streamlined care pathways is vital. Moreover, targeted regional strategies that address local healthcare needs and economic environments are essential to capture untapped market segments and drive sustainable growth.

Conclusion: A Forward Path in BPH Treatment Innovation and Market Expansion

The evolving dynamics of the BPH treatment market underscore significant progress in medical innovation and a shift toward more patient-focused therapeutic solutions. Advances in minimally invasive procedures, enhanced product technologies, and improved diagnostic methodologies collectively paint a picture of a market poised for substantial growth. The convergence of clinical excellence with strategic market segmentation has enabled stakeholders to better understand patient needs and tailor interventions accordingly. This, combined with robust regional growth patterns and a competitive environment driven by industry leaders, creates an ecosystem where innovation and patient care are paramount.

In summary, the market stands at an inflection point where technological advancements and strategic collaborations can forge a future marked by improved outcomes and increased accessibility to cutting-edge treatments. With clear insights and actionable strategies in place, stakeholders are well-equipped to navigate the complexities of the competitive landscape and drive meaningful value in the BPH treatment space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and improved diagnosis of benign prostatic hyperplasia conditions
      • 5.1.1.2. Growing patient awareness and preference for effective non-surgical treatment options
      • 5.1.1.3. Expansion of healthcare infrastructure globally
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness about benign prostatic hyperplasia symptoms
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations in minimally invasive treatments for benign prostatic hyperplasia
      • 5.1.3.2. Leveraging big data analytics to enhance benign prostatic hyperplasia diagnostic and treatment processes
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities for benign prostatic hyperplasia treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing preference for benign prostatic hyperplasia treatment using medication and surgical treatment
    • 5.2.2. End User: Increasing use of benign prostatic hyperplasia treatment in ambulatory surgical centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. 5-Alpha-Reductase Inhibitors
    • 6.2.2. Alpha Blockers
  • 6.3. Minimally Invasive Therapies
    • 6.3.1. Prostate Artery Embolization
    • 6.3.2. Water Vapour Therapy
  • 6.4. Surgical Treatments
    • 6.4.1. Laser Surgery
    • 6.4.2. Prostatic Urethral Lift
    • 6.4.3. Transurethral Incision Of The Prostate
    • 6.4.4. Transurethral Resection Of The Prostate

7. Benign Prostatic Hyperplasia Treatment Market, by Product Type

  • 7.1. Introduction
  • 7.2. Catheters
  • 7.3. Electrodes
  • 7.4. Implants
  • 7.5. Prostatic Stents
  • 7.6. Resectoscopes
  • 7.7. Urology Laser

8. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Benign Prostatic Hyperplasia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Mount Sinai launches a new robotic system for treating an enlarged prostate.
    • 12.3.2. Zenflow secures USD 24 million Series C to drive FDA pre-market approval and commercialization of Spring System
    • 12.3.3. Rivermark Medical secures USD 30 million Series C investment for development of FloStent
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Asahi Kasei Corporation
  • 4. Astellas Pharma Inc.
  • 5. Bayer AG
  • 6. Boehringer Ingelheim GmbH
  • 7. Boston Scientific Corporation
  • 8. Cipla Ltd.
  • 9. Dr. Reddy's Laboratories
  • 10. Eli Lilly and Company
  • 11. Endo International PLC
  • 12. GlaxoSmithKline plc
  • 13. Hikma Pharmaceuticals PLC
  • 14. Lumenis Ltd.
  • 15. Lupin Pharmaceuticals
  • 16. Medtronic PLC
  • 17. Merck & Co., Inc.
  • 18. Merit Medical Systems
  • 19. Mylan N.V.
  • 20. Olympus Corporation
  • 21. Pfizer, Inc.
  • 22. Sanofi S.A.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Teleflex Incorporated
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)

TABLE